UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

DNA damaging agents and immunotherapy in NSCLC: Is there a STING in the tale?

Annals of oncology, 2018-10, Vol.29, p.viii45-viii45

2018

Volltextzugriff (PDF)

242 BMN 673 as single agent and in combination with temozolomide or PI3K pathway inhibitors in small cell lung cancer and gastric cancer models

European journal of cancer (1990), 2014-11, Vol.50, p.81-81

2014

Volltextzugriff (PDF)

A high-throughput drug screen identifies new therapeutic vulnerabilities in non-small cell lung cancers (NSCLC) with overexpression of the EMT-associated receptor tyrosine kinase AXL

European journal of cancer (1990), 2016-12, Vol.69, p.S82-S82

2016

Volltextzugriff (PDF)

Polymorphisms in Genes Involved in Nitric Oxide (NO) Signaling and the Risk for Late Normal Tissue Injury From Radiation Therapy (RT)

International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (3), p.S682-S682

2012

Volltextzugriff (PDF)

Genomic landscape of small cell neuroendocrine cervical cancer

Gynecologic oncology, 2018-06, Vol.149 (3), p.626-627

2018

Volltextzugriff (PDF)

163P Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: Findings from the CAVE-lung trial

Annals of oncology, 2022-04, Vol.33, p.S107-S108

2022

Volltextzugriff (PDF)

SCLC subtype-enriched biomarkers define positioning of Aurora B inhibitor combination with venetoclax

European journal of cancer (1990), 2020-10, Vol.138, p.S47-S47

2020

Volltextzugriff (PDF)

1735P SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models

Annals of oncology, 2020-09, Vol.31, p.S1015-S1015

2020

Volltextzugriff (PDF)

1745P SARS-CoV-2 infects metabolically-primed epithelial cells in lung cancer models

Annals of oncology, 2020-09, Vol.31, p.S1019-S1019

2020

Volltextzugriff (PDF)

1736P Elevated AXL expression following SARS-CoV-2 infection in non-small cell lung cancer

Annals of oncology, 2020-09, Vol.31, p.S1015-S1016

2020

Volltextzugriff (PDF)

142PDNA damaging agents and immunotherapy in NSCLC: Is there a STING in the tale?

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

OA03.06 ASCL1, NEUROD1, and POU2F3 Drive Distinct Subtypes of Small Cell Lung Cancer with Unique Therapeutic Vulnerabilities

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S213-S213

2019

Volltextzugriff (PDF)

1749PActivity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

245 - A high-throughput drug screen identifies new therapeutic vulnerabilities in non-small cell lung cancers (NSCLC) with overexpression of the EMT-associated receptor tyrosine kinase AXL

European journal of cancer (1990), 2016-12, Vol.69, p.S82-S82

2016

Volltextzugriff (PDF)

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition

Clinical cancer research, 2016-02, Vol.22 (3), p.609-620

2016

Volltextzugriff (PDF)

AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors

Molecular cancer research, 2021-03, Vol.19 (3), p.485-497

2021

Volltextzugriff (PDF)

Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2–Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology

Journal of thoracic oncology, 2021-11, Vol.16 (11), p.1821-1839

2021

Volltextzugriff (PDF)

Comparative genomics of high grade neuroendocrine carcinoma of the cervix

PloS one, 2020-06, Vol.15 (6), p.e0234505-e0234505

2020

Volltextzugriff (PDF)

Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer

Cancer & metabolism, 2021-09, Vol.9 (1), p.33-33, Article 33

2021

Volltextzugriff (PDF)

Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies

Oncotarget, 2017-09, Vol.8 (43), p.73419-73432

2017

Volltextzugriff (PDF)

SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer

Translational lung cancer research, 2021-11, Vol.10 (11), p.4095-4105

2021

Volltextzugriff (PDF)

Sepiapterin ameliorates chemically induced murine colitis and azoxymethane-induced colon cancer

The Journal of pharmacology and experimental therapeutics, 2013-10, Vol.347 (1), p.117-125

2013

Volltextzugriff (PDF)

Abstract 232: Comprehensive metabolic profiling and vulnerabilities to metabolic inhibitors among small cell lung cancer subtypes

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.232-232

2020

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(34)

Sprache

Englisch
(34)

Erscheinungsjahr

n.n

Thema

Science & Technology
(11)
Life Sciences & Biomedicine
(9)
Oncology
(9)
Humans
(6)
Cell Biology
(4)
Cell Line, Tumor
(4)
Animals
(3)
Biomarkers
(3)
Hematology, Oncology And Palliative Medicine
(3)
Lung Cancer
(3)
Lung Neoplasms - Drug Therapy
(3)
Mice
(3)
Sclc
(3)
Tumors
(3)
Apoptosis
(2)
Cancer
(2)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(2)
Carcinoma, Non-Small-Cell Lung - Pathology
(2)
Cluster Analysis
(2)
Drug Resistance, Neoplasm - Genetics
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

DNA damaging agents and immunotherapy in NSCLC: Is there a STING in the tale?

242 BMN 673 as single agent and in combination with temozolomide or PI3K pathway inhibitors in small cell lung cancer and gastric cancer models

A high-throughput drug screen identifies new therapeutic vulnerabilities in non-small cell lung cancers (NSCLC) with overexpression of the EMT-associated receptor tyrosine kinase AXL

Polymorphisms in Genes Involved in Nitric Oxide (NO) Signaling and the Risk for Late Normal Tissue Injury From Radiation Therapy (RT)

Genomic landscape of small cell neuroendocrine cervical cancer

163P Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: Findings from the CAVE-lung trial

SCLC subtype-enriched biomarkers define positioning of Aurora B inhibitor combination with venetoclax

1735P SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models

1745P SARS-CoV-2 infects metabolically-primed epithelial cells in lung cancer models

1736P Elevated AXL expression following SARS-CoV-2 infection in non-small cell lung cancer

142PDNA damaging agents and immunotherapy in NSCLC: Is there a STING in the tale?

OA03.06 ASCL1, NEUROD1, and POU2F3 Drive Distinct Subtypes of Small Cell Lung Cancer with Unique Therapeutic Vulnerabilities

1749PActivity of the novel Aurora kinase B inhibitor AZD2811 in biomarker-defined models of small cell lung cancer

245 - A high-throughput drug screen identifies new therapeutic vulnerabilities in non-small cell lung cancers (NSCLC) with overexpression of the EMT-associated receptor tyrosine kinase AXL

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition

An Epithelial―Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities

AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors

Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2–Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology

Comparative genomics of high grade neuroendocrine carcinoma of the cervix

Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer

Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies

SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer

Sepiapterin ameliorates chemically induced murine colitis and azoxymethane-induced colon cancer

Abstract 232: Comprehensive metabolic profiling and vulnerabilities to metabolic inhibitors among small cell lung cancer subtypes

Suchergebnisse filtern